1 Introduction Endometrial cancer (EC) is the most common gynecologic malignancy in developed countries, with its incidence continuing to rise due to aging populations and increasing obesity rates. While early-stage endometrioid endometrial cancer generally has a favourable prognosis, advanced or recurrent EC remains challenging to treat and is often associated with poor clinical outcomes [1-3].